Arena Pharmaceuticals, Inc. (ARNA): What Do The Smartest Investors Think?

Is Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) a safe stock to buy now? Hedge funds are turning bullish. The number of long hedge fund bets increased by 2 lately.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)In the financial world, there are tons of indicators investors can use to watch their holdings. Some of the most under-the-radar are hedge fund and insider trading sentiment. At Insider Monkey, our research analyses have shown that, historically, those who follow the top picks of the best fund managers can outperform the market by a very impressive margin (see just how much).

Just as integral, bullish insider trading sentiment is a second way to parse down the investments you’re interested in. There are lots of motivations for an upper level exec to sell shares of his or her company, but just one, very simple reason why they would buy. Several academic studies have demonstrated the valuable potential of this method if “monkeys” know where to look (learn more here).

Keeping this in mind, it’s important to take a glance at the key action encompassing Arena Pharmaceuticals, Inc. (NASDAQ:ARNA).

How have hedgies been trading Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)?

At the end of the first quarter, a total of 13 of the hedge funds we track were long in this stock, a change of 18% from the first quarter. With the smart money’s sentiment swirling, there exists an “upper tier” of noteworthy hedge fund managers who were increasing their holdings significantly.

When looking at the hedgies we track, James E. Flynn’s Deerfield Management had the largest position in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), worth close to $43.9 million, accounting for 2.6% of its total 13F portfolio. Sitting at the No. 2 spot is Peter Rathjens, Bruce Clarke and John Campbell of Arrowstreet Capital, with a $7.7 million position; the fund has 0.1% of its 13F portfolio invested in the stock. Other peers with similar optimism include Daniel Gold’s QVT Financial, and Robert Pohly’s Samlyn Capital.

With a general bullishness amongst the heavyweights, some big names were breaking ground themselves. Arrowstreet Capital, managed by Peter Rathjens, Bruce Clarke and John Campbell, created the most outsized position in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA). Arrowstreet Capital had 7.7 million invested in the company at the end of the quarter. Robert Pohly’s Samlyn Capital also made a $3.6 million investment in the stock during the quarter. The other funds with new positions in the stock are Daniel S. Och’s OZ Management and Gabe Hoffman’s Accipiter Capital Management.

How have insiders been trading Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)?

Insider trading activity, especially when it’s bullish, is particularly usable when the company in focus has experienced transactions within the past half-year. Over the latest 180-day time frame, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has experienced zero unique insiders purchasing, and 2 insider sales (see the details of insider trades here).

With the results shown by Insider Monkey’s tactics, everyday investors must always pay attention to hedge fund and insider trading sentiment, and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) applies perfectly to this mantra.

Click here to learn why you should track hedge funds

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 10 Largest Pharmaceutical Companies In the World

The 10 Most Expensive Android Apps

The 9 Most Expensive Designer Bags in the World

The 7 Most Expensive Real Estate in the World

The 10 Most Expensive eBay Items Ever Sold

The 10 Most Expensive iPhone Apps

The 9 Most Expensive Designer Shoes in the World

The 10 Most Expensive Cigarette Brands

The 10 Most Expensive Law Schools in the US

The 10 Best Wall Street Movies

The 10 Most Expensive Golf Clubs Ever Sold

The 10 Most Expensive Golf Memberships

The 10 Best Disney Characters Ever Created

The 8 Best Foods for Gaining Weight

The 10 Most Expensive Colleges in the World

The 7 Most Memorable Ad Campaigns of All Time

The 7 Most Expensive High Schools in the World

The 10 Electric Vehicles with the Longest Range

The 10 Cities with the Worst Drivers in the World

The 10 Most Expensive Dresses Ever Created

10 Islands to Visit Before You Die

10 Famous Celebrities Who Needed Rehab

The 15 Countries with the Largest Oil Reserves

The 10 Most Overused Excuses in the World

The 5 Best iOS Apps You Can’t Get on Android

5 Companies Damaged By Social Media Blunders

The 10 Most Legendary Blues Songs

The 10 Most Lawless Places in the World

4 Reasons China is a Threat to the US

The 17 Most Sugary Drinks in the World

The 10 Most Ruthless Rulers in History

The 10 Greatest Generals in History

Top 8 Travel Destinations for 2015

The 10 Safest Dog Breeds for Children

The 10 Most Stolen Vehicles in the US

The 7 Most Expensive Celebrity Weddings

The 10 Best LoL Teams in the World

Top 10 Worst Marketing Campaigns Ever Produced

Top 5 Diets that Help You Lose Weight

The 10 Best Ways to Stay Awake

7 Artists That Switched Musical Genres

The 10 Most Expensive Cities to Live in New Jersey

The 10 Best High Schools in New York

The 10 Countries With the Least Gender Inequality

The 6 Biggest Musician-Manager Feuds

The 10 Countries with the Cheapest Gas Prices

The 7 Most Theatrical Bands of All Time

The 8 Worst Band Breakups of All Time

The 10 Most Important South American Leaders

The 7 Most Successful Casting Show Winners

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!